Martin Harp

4 days ago | modernretina.com | Martin Harp

Ocular Therapeutix has closed enrollment in its SOL-R registrational trial of its product candidate AXPAXLI (also known as OTX-TKI) in wet age-related macular degeneration (wet AMD). AXPAXLI is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small-molecule, multi-target tyrosine kinase inhibitor (TKI) with anti-angiogenic properties.

5 days ago | ophthalmologytimes.com | Martin Harp

Ocular Therapeutix has closed enrollment in its SOL-R registrational trial of its product candidate AXPAXLI (also known as OTX-TKI) in wet age-related macular degeneration (wet AMD). AXPAXLI is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small-molecule, multi-target tyrosine kinase inhibitor (TKI) with anti-angiogenic properties.

5 days ago | ophthalmologytimes.com | Martin Harp

Opus Genetics has released positive topline results from LYNX-2, its phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Phentolamine ophthalmic solution 0.75% is a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size.

1 week ago | ophthalmologytimes.com | Dilsher S. Dhoot |Mark R. Barakat |Martin Harp |Hattie Hayes

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg versus 2 mg during the matched dosing phase, and outcomes of shortened, maintained, or extended dosing intervalsEditor's note: The below transcript has been lightly edited for clarity. Hi, I'm here at ARVO 2025, and I'm presenting a poster for EYLEA HD and looking specifically at the PHOTON data. This is a post-hoc analysis.

1 week ago | optometrytimes.com | Martin Harp

Iolyx Therapeutics announced top-line data from its phase 2 trial of ILYX-002 for the treatment of moderate-to-severe dry eye disease (DED) associated with systemic autoimmune or inflammatory conditions. The trial is a randomized, double-masked, and vehicle-controlled study conducted at multiple sites across Australia.